PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 161 filers reported holding PROGENICS PHARMACEUTICALS IN in Q1 2017. The put-call ratio across all filers is 0.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $152,000 | -79.7% | 22,433 | -71.7% | 0.00% | -81.0% |
| Q1 2017 | $749,000 | +77.5% | 79,369 | +62.5% | 0.02% | +110.0% |
| Q4 2016 | $422,000 | +85.9% | 48,836 | +36.2% | 0.01% | +100.0% |
| Q3 2016 | $227,000 | +23.4% | 35,845 | -18.0% | 0.01% | +25.0% |
| Q2 2016 | $184,000 | +65.8% | 43,712 | +71.0% | 0.00% | +33.3% |
| Q1 2016 | $111,000 | -28.4% | 25,570 | +1.2% | 0.00% | 0.0% |
| Q4 2015 | $155,000 | -20.5% | 25,277 | -25.7% | 0.00% | 0.0% |
| Q3 2015 | $195,000 | -44.1% | 34,027 | -27.2% | 0.00% | -50.0% |
| Q2 2015 | $349,000 | +301.1% | 46,752 | +222.8% | 0.01% | +200.0% |
| Q1 2015 | $87,000 | -56.3% | 14,482 | -44.9% | 0.00% | -33.3% |
| Q4 2014 | $199,000 | +176.4% | 26,292 | +88.4% | 0.00% | +200.0% |
| Q3 2014 | $72,000 | +41.2% | 13,958 | +11.0% | 0.00% | 0.0% |
| Q1 2014 | $51,000 | -50.0% | 12,578 | -37.9% | 0.00% | 0.0% |
| Q3 2013 | $102,000 | – | 20,267 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARDSLEY ADVISORY PARTNERS LP | 1,255,000 | $5,823,000 | 1.12% |
| Phocas Financial Corp. | 1,146,292 | $5,319,000 | 0.54% |
| Worth Venture Partners, LLC | 138,357 | $641,000 | 0.36% |
| RICE HALL JAMES & ASSOCIATES, LLC | 2,293,179 | $10,640,000 | 0.34% |
| Monashee Investment Management LLC | 240,000 | $1,114,000 | 0.26% |
| BKS ADVISORS, LLC | 118,587 | $550,000 | 0.22% |
| PINNACLE ASSOCIATES LTD | 1,418,391 | $6,581,000 | 0.15% |
| FARALLON CAPITAL MANAGEMENT LLC | 4,200,820 | $19,492,000 | 0.15% |
| Fosun International Ltd | 472,580 | $2,174,000 | 0.14% |
| CARILLON TOWER ADVISERS, INC. | 3,948,024 | $18,318,000 | 0.13% |